Al­lo­ri­on rais­es $50M Se­ries B; AskBio gets a new CEO

Al­lo­ri­on Ther­a­peu­tics has raised an­oth­er $50 mil­lion in a Se­ries B fi­nanc­ing round to get Phase I/II clin­i­cal tri­als in both Chi­na and the US off the ground, the on­col­o­gy and au­toim­mune dis­ease-fo­cused biotech an­nounced Thurs­day.

The biotech has raised $90 mil­lion since its be­gin­ning in 2020 with co-founders Pe­ter Ding and Fang Li. Gre­go­ry Berk has al­so joined Al­lo­ri­on as CMO to de­sign and over­see the tri­als and build out the clin­i­cal teams in the com­pa­ny’s lo­ca­tions in the US and Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER